Gilead and Merck Report Mixed Results: HIV Pill Success, Lung Cancer Trial Failure
Gilead and Merck announced that their experimental once-weekly HIV pill successfully suppressed the virus in two large trials, while simultaneously revealing that their combination lung cancer therapy failed to meet primary endpoints in a Phase 3 study. The HIV pill represents progress toward more convenient long-acting treatments, while the cancer trial failure is a setback for Gilead's oncology portfolio. These results highlight the unpredictable nature of drug development and the competitive landscape in both HIV and cancer therapeutics.
Gilead Sciences and Merck reported contrasting clinical trial outcomes in a busy news cycle for the two pharmaceutical companies. Their experimental HIV pill, which combines Merck's islatravir and Gilead's lenacapavir, successfully suppressed the virus when dosed once weekly in two large trials, positioning it as part of a broader industry shift toward longer-acting HIV treatments that could improve patient convenience and adherence. Conversely, the companies announced early termination of the EVOKE-03 Phase 3 trial evaluating Gilead's Trodelvy combined with Merck's Keytruda for non-small cell lung cancer, as the combination failed to demonstrate statistically significant improvement in progression-free survival compared to Keytruda alone. The lung cancer setback is particularly significant for Gilead, whose Trodelvy has struggled to show benefit across multiple cancer types despite initial promise. Merck faces less impact from the failure since it is developing a competing TROP-2-targeted therapy with Chinese biotech Kelun that showed stronger efficacy in recent studies.
What's missing
The articles do not discuss the broader implications for HIV treatment accessibility in resource-limited settings, nor do they address patient perspectives on the convenience benefits of once-weekly dosing versus existing options. Additionally, there is limited discussion of the timeline for regulatory approval or commercial availability of the HIV pill.
How coverage differed
STAT News presented both results factually and sequentially without editorial judgment, allowing readers to understand the mixed outcomes. The framing emphasizes scientific data and competitive implications rather than celebrating or criticizing either company, which is appropriate for a specialized healthcare publication serving industry professionals.
What different sources said
- STAT NewsCenter
Gilead and Merck’s latest trial success and flop
Related
WHO and Africa CDC Launch $518 Million Emergency Response to Ebola Outbreak
The World Health Organization and Africa Centres for Disease Control and Prevention announced a $518 million joint emergency response program to combat an ongoing Ebola outbreak primarily affecting Congo and Uganda. The six-month initiative, following a unified "One-Response" approach, comes as case numbers continue to rise despite earlier WHO estimates suggesting fewer cases than previously thought. The response is significant because the current Bundibugyo strain has a 25-50% fatality rate and no approved targeted treatments exist, making coordinated international action critical.
People increasingly turn to AI chatbots for health information, revealing gaps in healthcare access
A new study published in Nature Health examines how people are using AI chatbots to answer health and wellness questions, highlighting a trend of seeking medical information through artificial intelligence. This reflects broader challenges in healthcare accessibility and the quality of health information available online. The findings raise important questions about the responsibilities of AI companies in providing accurate health guidance and the adequacy of traditional healthcare provision.
UK Government Proposes Updates to School Food Standards to Reduce Unhealthy Options
The UK government is proposing changes to school food standards that would remove deep-fried foods and fruit juice while limiting pizza availability. The updates aim to increase fiber content and reduce fat, sugar, and salt in meals served to secondary school students. The changes reflect growing concerns about student nutrition and dietary health in educational settings.